|
SI2258847T1
(sl)
|
2002-08-05 |
2017-08-31 |
Silence Therapeutics Gmbh |
Nadaljnje nove oblike molekul interferenčne RNA
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
ATE485394T1
(de)
*
|
2003-06-02 |
2010-11-15 |
Univ Massachusetts |
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
|
|
US7750144B2
(en)
*
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
CA2528012C
(en)
*
|
2003-06-02 |
2015-11-24 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of rna silencing
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
DK2821085T3
(da)
*
|
2003-09-12 |
2020-08-03 |
Univ Massachusetts |
Rna-interferens til behandling af "gain-of-function"-forstyrrelser
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
EP2514758B2
(en)
*
|
2004-03-15 |
2021-06-23 |
City of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
EP1937066A4
(en)
*
|
2005-08-18 |
2008-12-24 |
Alnylam Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
|
|
HUE037173T2
(hu)
|
2006-08-08 |
2018-08-28 |
Univ Bonn Rheinische Friedrich Wilhelms |
5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
TWI455944B
(zh)
*
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
WO2010021718A1
(en)
|
2008-08-19 |
2010-02-25 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
|
US8225729B2
(en)
*
|
2008-12-16 |
2012-07-24 |
Kimberly-Clark Worldwide, Inc. |
Three-dimensional wiping substrate and method therefor
|
|
EP2379083B1
(en)
*
|
2008-12-18 |
2017-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
US11408003B2
(en)
|
2008-12-18 |
2022-08-09 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
US20120022142A1
(en)
*
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
KR101791702B1
(ko)
*
|
2009-04-03 |
2017-10-30 |
다이서나 파마수이티컬, 인크. |
비대칭 이중가닥 ｒｎａ에 의한 ｋｒａｓ의 특이적 저해를 위한 방법 및 조성물
|
|
EP2756845B1
(en)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
US20120114710A1
(en)
*
|
2009-05-18 |
2012-05-10 |
Lynn Kirkpatrick |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
CN102803496A
(zh)
|
2009-06-10 |
2012-11-28 |
淡马锡生命科学研究院有限公司 |
用于棉花中基因功能性分析的病毒诱导的基因沉默(vigs)
|
|
EP2449114B9
(en)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
US8916693B2
(en)
|
2009-09-17 |
2014-12-23 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
KR101692063B1
(ko)
|
2009-12-09 |
2017-01-03 |
닛토덴코 가부시키가이샤 |
hsp47 발현의 조절
|
|
WO2011072292A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of rna and rna derivatives
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
JP2013534424A
(ja)
|
2010-07-06 |
2013-09-05 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッド |
二本鎖ｒｎａによるアンドロゲン受容体の特異的阻害に対する方法と化合物
|
|
EP3587579B1
(en)
|
2010-07-06 |
2021-03-03 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
MX2013003681A
(es)
|
2010-10-01 |
2013-11-20 |
Moderna Therapeutics Inc |
Ácidos nucleicos manipulados y métodos de uso de los mismos.
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012056440A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
|
SG192961A1
(en)
|
2011-03-03 |
2013-09-30 |
Quark Pharmaceuticals Inc |
Compositions and methods for treating lung disease and injury
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
BR112013031723B1
(pt)
|
2011-06-10 |
2020-10-13 |
Temasek Life Sciences Laboratory Limited |
construção de polinucleotídeo, método para transformação de uma célula fúngica e promotor isolado
|
|
WO2012173994A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of nucleic acid payloads
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
SI3682905T1
(sl)
|
2011-10-03 |
2022-04-29 |
Modernatx, Inc. |
Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
|
|
AU2012325997C1
(en)
|
2011-10-18 |
2018-07-05 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
|
JP2015502931A
(ja)
|
2011-11-18 |
2015-01-29 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
修飾ＲＮＡｉ剤
|
|
US20130156849A1
(en)
|
2011-12-16 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
EP3988104A1
(en)
|
2012-02-24 |
2022-04-27 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
HK1206601A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
IN2014KN02312A
(show.php)
|
2012-04-19 |
2015-05-01 |
Temasek Life Sciences Lab Ltd |
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
SI2922554T1
(sl)
|
2012-11-26 |
2022-06-30 |
Modernatx, Inc. |
Terminalno modificirana RNA
|
|
JP2016501533A
(ja)
*
|
2012-12-14 |
2016-01-21 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
二本鎖ｒｎａによるｃｋａｐ５の特異的阻害に関する方法および組成物
|
|
CN105142614A
(zh)
|
2013-03-14 |
2015-12-09 |
迪克纳制药公司 |
用于配制阴离子试剂的方法
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
JP2016528887A
(ja)
|
2013-07-03 |
2016-09-23 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
二本鎖ＲＮＡによるα−１アンチトリプシンの特異的阻害のための方法及び組成物
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
|
EP3077511A4
(en)
|
2013-12-06 |
2017-07-05 |
Dicerna Pharmaceuticals Inc. |
Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
|
|
HUE055470T2
(hu)
|
2013-12-27 |
2021-11-29 |
Dicerna Pharmaceuticals Inc |
Eljárások és kompozíciók a glikolát-oxidáz (HAO1) kettõs szálú RNA általi specifikus gátlására
|
|
DK3204497T3
(da)
|
2014-10-10 |
2020-05-25 |
Dicerna Pharmaceuticals Inc |
Terapeutisk hæmning af lactatdehydrogenase og midler dertil
|
|
WO2016064347A1
(en)
|
2014-10-22 |
2016-04-28 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
|
EP3569711B1
(en)
|
2014-12-15 |
2021-02-03 |
Dicerna Pharmaceuticals, Inc. |
Ligand-modified double-stranded nucleic acids
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
WO2016183009A2
(en)
|
2015-05-08 |
2016-11-17 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
|
|
WO2017004357A1
(en)
*
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
PL3506909T3
(pl)
|
2016-09-02 |
2022-09-12 |
Dicerna Pharmaceuticals, Inc. |
Analogi 4’- fosforanu i zawierające je oligonukleotydy
|
|
WO2019074071A1
(ja)
*
|
2017-10-11 |
2019-04-18 |
日東電工株式会社 |
核酸分子発現の調節
|
|
RS64483B1
(sr)
|
2017-10-13 |
2023-09-29 |
Novo Nordisk Healthcare Ag |
Postupci i kompozicije za inhibiciju ekspresije ldha
|
|
CN111372593B
(zh)
|
2017-10-20 |
2024-03-19 |
戴瑟纳制药公司 |
治疗乙型肝炎感染的方法
|
|
US11813280B2
(en)
|
2018-01-05 |
2023-11-14 |
Dicerna Pharmaceuticals, Inc. |
Reducing beta-catenin and IDO expression to potentiate immunotherapy
|
|
CN111601891A
(zh)
|
2018-01-16 |
2020-08-28 |
迪克纳制药公司 |
用于抑制aldh2表达的组合物和方法
|
|
JP7616987B2
(ja)
|
2018-07-13 |
2025-01-17 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
|
|
EP3846797A4
(en)
|
2018-09-04 |
2022-06-08 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
USE OF DELTA-TOCOTRIENOL TO TREAT CANCER
|
|
US11452738B2
(en)
|
2019-01-04 |
2022-09-27 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
|
|
WO2020167593A1
(en)
|
2019-02-12 |
2020-08-20 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for inhibiting expression of cyp27a1
|
|
EP3947681A1
(en)
|
2019-03-29 |
2022-02-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
AU2020252560A1
(en)
|
2019-04-04 |
2021-10-28 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
|
EP3963072A1
(en)
|
2019-05-03 |
2022-03-09 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
AU2020336121A1
(en)
|
2019-08-30 |
2022-03-24 |
Dicerna Pharmaceuticals, Inc. |
Ligand-2'-modified nucleic acids, synthesis thereof and intermediate compounds thereof
|
|
US20220389430A1
(en)
|
2019-10-02 |
2022-12-08 |
Dicema Pharmaceuticals, Inc. |
Chemical modifications of small interfering rna with minimal fluorine content
|
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
|
WO2021130270A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
BR112022018667A2
(pt)
|
2020-03-18 |
2022-11-29 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para inibir a expressão de ang-ptl3
|
|
CA3187220A1
(en)
|
2020-08-04 |
2022-02-10 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
|
AU2021321430A1
(en)
|
2020-08-04 |
2023-03-02 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting PLP1 expression
|
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
|
EP4192955A1
(en)
|
2020-08-05 |
2023-06-14 |
F. Hoffmann-La Roche AG |
Oligonucleotide treatment of hepatitis b patients
|
|
KR20250077604A
(ko)
|
2020-08-05 |
2025-05-30 |
다이서나 파마수이티컬, 인크. |
Lpa 발현을 저해하기 위한 조성물 및 방법
|
|
MX2023012048A
(es)
|
2021-04-12 |
2023-10-23 |
Boehringer Ingelheim Int |
Composiciones y metodos para inhibir cetohexoquinasa (khk).
|
|
BR112023021109A2
(pt)
|
2021-04-14 |
2023-12-12 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para modular a expressão de pnpla3
|
|
TWI849410B
(zh)
|
2021-04-19 |
2024-07-21 |
美商戴瑟納製藥股份有限公司 |
用於抑制核受體亞家族１群組ｈ成員３（ｎｒ１ｈ３）表現的組成物和方法
|
|
JP7463621B2
(ja)
|
2021-05-28 |
2024-04-08 |
ノヴォ ノルディスク アー／エス |
ミトコンドリアアミドキシム還元成分１（ｍａｒｃ１）発現を阻害するための組成物および方法
|
|
TW202308660A
(zh)
|
2021-08-25 |
2023-03-01 |
美商戴瑟納製藥股份有限公司 |
用於抑制α－１抗胰蛋白酶表現之組合物及方法
|
|
EP4430184A2
(en)
|
2021-11-11 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Pharmaceutical combinations for treatment of hbv
|
|
AU2022402155A1
(en)
|
2021-12-01 |
2024-05-09 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating apoc3 expression
|
|
EP4508218A1
(en)
|
2022-04-15 |
2025-02-19 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for modulating scap activity
|
|
IL316934A
(en)
|
2022-05-12 |
2025-01-01 |
Dicerna Pharmaceuticals Inc |
Compounds and methods for inhibiting MAPT expression
|
|
CN119630791A
(zh)
|
2022-05-13 |
2025-03-14 |
迪克纳制药公司 |
用于抑制snca表达的组合物和方法
|
|
TWI868755B
(zh)
|
2022-06-24 |
2025-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
|
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
AR133386A1
(es)
|
2023-07-28 |
2025-09-24 |
Dicerna Pharmaceuticals Inc |
Composiciones y métodos para la expresión del receptor del ligando de muerte programada (pd-l1)
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|